On the whole, as suggested from the mentioned results, the expression of diagnostic markers ERCC5, HES6 and RORA (AUC > 0.8) is correlated with the progression of CAD and they may be used as biomarkers to assess the pathogenesis of CAD and validate the effectiveness of CAD treatment. Here, RORA is linked to coronary artery disorder.